What are the efficacy and indications of 0.01% atropine sulfate eye drops (EIKANCE)

0.01% Atropine Sulfate Eye Drops (EIKANCE) is a low-concentration atropine preparation that has received widespread attention in the field of myopia prevention and control in children and adolescents in recent years. Atropine, as a classic anticholinergic drug, blocks the stimulation of the ciliary muscle by parasympathetic nerves and inhibits eye adjustment activities, thereby slowing down the growth rate of the ocular axis. This is its core mechanism of action in myopia management. The low-concentration design allows EIKANCE to maintain efficacy while significantly reducing the mydriasis and accommodation dysfunction caused by traditional high-concentration atropine, thereby improving patient comfort and long-term compliance.

In terms of efficacy,EIKANCE 0.01% mainly reduces the axial length growth caused by excessive adjustment of the eye by weakening the ciliary muscle contraction response. This mechanism of action has been verified by many international research studies, and is especially suitable for school-age children and adolescents, and can effectively delay the progression of myopia. Compared with high-concentration atropine, low-concentration preparations not only retain the myopia control effect, but also reduce side effects such as pupil dilation and difficulty in near adjustment, allowing children to have a more natural visual experience in daily life and learning. In addition, the low concentration of EIKANCE reduces the impact on light sensitivity, so no special optical protection is required during indoor and outdoor activities. This is especially important for school-age children, because light changes frequently and excessive light sensitivity may affect the comfort of daily learning and outdoor activities.

In terms of indications,EIKANCE is mainly targeted at children and adolescents with early myopia, especially those at risk of rapid axial growth. Clinical practice and overseas guidelines generally believe that the key to preventing and controlling myopia in children lies in early intervention. Continuous low-concentration atropine eye drops can effectively delay the progression of myopia at a stage when the axial length of the eye is not excessively elongated. Although EIKANCE has limited effectiveness in correcting astigmatism or hyperopia, it has potential value in controlling myopia and preventing complications associated with high myopia, such as retinal degeneration, glaucoma, and macular degeneration. The use of low-concentration atropine is not only suitable for individual intervention, but also as part of a comprehensive prevention and control plan, combined with glasses, orthokeratology lenses and behavioral intervention to optimize overall visual health management.

EIKANCE is usually administered as a once-daily infusion into one or both eyes. The drug is absorbed into the intraocular tissue through the cornea and exerts a local inhibition of ciliary muscle activity. The low-concentration design results in extremely low systemic absorption of the drug in the body, significantly reducing the risk of side effects and ensuring long-term safety. Overseas clinical data show that long-term use of low-concentration atropine can maintain efficacy while having a low incidence of side effects and high patient compliance. This is also an important reason why it is gradually recommended in myopia prevention and control.

It is worth noting that EIKANCE is not used to correct existing refractive errors or astigmatism, but its main goal is to control axial growth. For children who already have high myopia or complex refractive problems, they still need to cooperate with traditional vision correction methods, and at the same time, the value of low-concentration atropine should be evaluated under the guidance of a doctor. Overseas experts recommend that a comprehensive eye examination should be conducted before using EIKANCE to evaluate the development speed of myopia, axial length and corneal health to develop a personalized intervention plan.

Reference materials:https://www.eikance.com.au/